this outcome after LVAD. For patients with advanced heart failure (HF), cardiac transplantation is epidemiologically insignificant at 2,200 patients per year in the United States, and the adverse event profile with long-term LVADs either as destination therapy or bridge to transplantation remains problematic.
Thus, a recovery strategy with a goal toward device explantation and sustained restoration of cardiac function is desirable and should be aggressively pursued. By current estimates, a substantial population of patients with advanced HF may be suitable candidates for recovery (5) , particularly younger, nonischemic patients with acute or short durations of HF (6) (7) (8) .
However, recovery rates among experienced LVAD centers are highly variable, with many centers reporting recovery rates of nearly 0%, perhaps because of limited clinical and research programs emphasizing recovery in otherwise stable LVAD patients (9) . As a result, the field of mechanical circulatory support remains in a state of cognitive dissonance over this important concept.
LVAD therapy serves as a powerful mechanical vehicle by which to actively recover the failing heart when medical therapy alone becomes insufficient to reverse the disease course. Conceivably, most patients experience favorable myocardial structural and molecular changes after left ventricular pressure and volume unloading and improved neurohormonal activation. What remains to be explored is whether a unique phenotype exists for those who sufficiently recover to allow for device explantation. This requires deeper phenotyping using tissue and clinical characterizations to distinguish those who completely recover from those who simply improve ("partially recover") with myocardial rest. Describing recovery as a continuum with biological remodeling and disease regression, against the current staging of HF, can guide the understanding of mechanisms and treatment goals at various stages along this pathway ( Figure 1 ).
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Device explant
The ACC/AHA stages suggest an "inviolate" progression to advanced HF stages that is typically irreversible (13) . In this hypothetical model, complete recovery and device explant could represent regression to stage A (normal structure, no symptoms), but these patients may remain "at high risk" for redeveloping heart failure. ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; HF ¼ heart failure;
LVAD ¼ left ventricular assist device; LVEF ¼ left ventricular ejection fraction.
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